Virtual Library
Start Your Search
Chiyoe Kitagawa
Author of
-
+
EP1.04 - Immuno-oncology (ID 194)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.04-33 - Pembrolizumab with High PD-L1: Who Are Non-Responders? (Now Available) (ID 3003)
08:00 - 18:00 | Author(s): Chiyoe Kitagawa
- Abstract
Background
Pembrolizumab is a programmed death-1 (PD-1) blockade which is approved for non-small cell lung cancer (NSCLC). It has been reported that programmed death-ligand 1 (PD-L1) high patients are more effective than low patients to pembrolizumab. It has not been clear what factors decide responsiveness to pembrolizumab in PD-L1 high patients.
Method
NSCLC patients who had been given pembrolizumab from April 2017 to October 2018 in Nagoya Medical Center and whose PD-L1 tumor proportion score (TPS) was ≥50% were included. A double cancer case was excluded. The non-effective group was made of patients who had stable and progressive diseases, and the effective group was made of patients who had complete and partial response. We compared the non-effective group with the effective group.
Result
Data were extracted retrospectively from patients' medical records. In total, 34 patients received pembrolizumab. One patient who had double cancer and 7 patients whose PD-L1 TPS was <50% were excluded from this analysis. Twenty-six patients were included. In 26 patients, 19 men (73.1%), 22 current or former smokers (84.6%). The median age was 69 (ranged 48–88). Patients with adenocarcinoma, adenosquamous, squamous, not otherwise specified, and pleomorphic carcinoma were 15/1/ 8/1/1. Stage IIIA, IIIB, IV, and recurrence after surgery were 1/2/16/ 7. Performance status (PS) 0, 1, 2, 3, and 4 were 7/9/7/ 2/1. First, second, and fourth lines of chemotherapy were 18, 7, and 1, respectively. Differences between pembrolizumab effective and non-effective group in gender, smoking history, age, tissue type, proportion of stage IV, and treatment line were not statistically different. In terms of PS, all PS 3 or 4 patients were non-effective.
Conclusion
In NSCLC PD-L1 high patients treated with pembrolizumab, PS 3–4 might be a factor, which indicated poor response to pembrolizumab.